186 related articles for article (PubMed ID: 24365504)
1. Factors affecting periprocedural morbidity and mortality and long-term patient survival after arterial embolization of hepatic neuroendocrine metastases.
Sofocleous CT; Petre EN; Gonen M; Reidy-Lagunes D; Ip IK; Alago W; Covey AM; Erinjeri JP; Brody LA; Maybody M; Thornton RH; Solomon SB; Getrajdman GI; Brown KT
J Vasc Interv Radiol; 2014 Jan; 25(1):22-30; quiz 31. PubMed ID: 24365504
[TBL] [Abstract][Full Text] [Related]
2. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
[TBL] [Abstract][Full Text] [Related]
3. Hepatic neuroendocrine metastases: chemo- or bland embolization?
Pitt SC; Knuth J; Keily JM; McDermott JC; Weber SM; Chen H; Rilling WS; Quebbeman EJ; Agarwal DM; Pitt HA
J Gastrointest Surg; 2008 Nov; 12(11):1951-60. PubMed ID: 18709512
[TBL] [Abstract][Full Text] [Related]
4. Hepatic neuroendocrine metastases: does intervention alter outcomes?
Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
[TBL] [Abstract][Full Text] [Related]
5. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors.
Ho AS; Picus J; Darcy MD; Tan B; Gould JE; Pilgram TK; Brown DB
AJR Am J Roentgenol; 2007 May; 188(5):1201-7. PubMed ID: 17449759
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry.
Wong TY; Zhang KS; Gandhi RT; Collins ZS; O'Hara R; Wang EA; Vaheesan K; Matsuoka L; Sze DY; Kennedy AS; Brown DB
BMC Cancer; 2022 Mar; 22(1):224. PubMed ID: 35232410
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.
Memon K; Lewandowski RJ; Mulcahy MF; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Gates VL; Atassi B; Newman S; Omary RA; Benson AB; Salem R
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):887-94. PubMed ID: 22137020
[TBL] [Abstract][Full Text] [Related]
9. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes.
Zener R; Yoon H; Ziv E; Covey A; Brown KT; Sofocleous CT; Thornton RH; Boas FE
Cardiovasc Intervent Radiol; 2019 Apr; 42(4):569-576. PubMed ID: 30627774
[TBL] [Abstract][Full Text] [Related]
10. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
Chen JX; Wileyto EP; Soulen MC
Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
[TBL] [Abstract][Full Text] [Related]
11. Embolotherapy for Neuroendocrine Tumor Liver Metastases: Prognostic Factors for Hepatic Progression-Free Survival and Overall Survival.
Chen JX; Rose S; White SB; El-Haddad G; Fidelman N; Yarmohammadi H; Hwang W; Sze DY; Kothary N; Stashek K; Wileyto EP; Salem R; Metz DC; Soulen MC
Cardiovasc Intervent Radiol; 2017 Jan; 40(1):69-80. PubMed ID: 27738818
[TBL] [Abstract][Full Text] [Related]
12. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference.
Kennedy A; Bester L; Salem R; Sharma RA; Parks RW; Ruszniewski P;
HPB (Oxford); 2015 Jan; 17(1):29-37. PubMed ID: 25186181
[TBL] [Abstract][Full Text] [Related]
13. DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.
Ziv E; Rice SL; Filtes J; Yarmohammadi H; Boas FE; Erinjeri JP; Petre EN; Brody LA; Brown KT; Covey AM; Getrajdman GI; Maybody M; Raj N; Sofocleous CT; Solomon SB; Reidy-Lagunes D
J Vasc Interv Radiol; 2018 Nov; 29(11):1519-1526. PubMed ID: 30342802
[TBL] [Abstract][Full Text] [Related]
14. Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.
Takaki H; Litchman T; Covey A; Cornelis F; Maybody M; Getrajdman GI; Sofocleous CT; Brown KT; Solomon SB; Alago W; Erinjeri JP
J Gastrointest Cancer; 2014 Dec; 45(4):494-9. PubMed ID: 25358551
[TBL] [Abstract][Full Text] [Related]
15. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.
Elf AK; Andersson M; Henrikson O; Jalnefjord O; Ljungberg M; Svensson J; Wängberg B; Johanson V
World J Surg; 2018 Feb; 42(2):506-513. PubMed ID: 29167951
[TBL] [Abstract][Full Text] [Related]
16. Hepatic artery embolization for neuroendocrine tumors: postprocedural management and complications.
Lewis MA; Jaramillo S; Roberts L; Fleming CJ; Rubin J; Grothey A
Oncologist; 2012; 17(5):725-31. PubMed ID: 22511263
[TBL] [Abstract][Full Text] [Related]
17. Hepatic artery chemoembolization or embolization for primary and metastatic liver tumors: post-treatment management and complications.
Berger DH; Carrasco CH; Hohn DC; Curley SA
J Surg Oncol; 1995 Oct; 60(2):116-21. PubMed ID: 7564377
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis.
Egger ME; Armstrong E; Martin RC; Scoggins CR; Philips P; Shah M; Konda B; Dillhoff M; Pawlik TM; Cloyd JM
J Am Coll Surg; 2020 Apr; 230(4):363-370. PubMed ID: 32032719
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil Lymphocyte Ratio and Transarterial Chemoembolization in Neuroendocrine Tumor Metastases.
McDermott SM; Saunders ND; Schneider EB; Strosberg D; Onesti J; Dillhoff M; Schmidt CR; Shirley LA
J Surg Res; 2018 Dec; 232():369-375. PubMed ID: 30463743
[TBL] [Abstract][Full Text] [Related]
20. 31P MR spectroscopy to evaluate the efficacy of hepatic artery embolization in the treatment of neuroendocrine liver metastases.
Ljungberg M; Westberg G; Vikhoff-Baaz B; Starck G; Wängberg B; Ekholm S; Ahlman H; Forssell-Aronsson E
Acta Radiol; 2012 Dec; 53(10):1118-26. PubMed ID: 23051638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
